Addex Therapeutics Ltd (ADXN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.233x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-765.84K) by net assets ($3.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Addex Therapeutics Ltd worth for the company's overall valuation and market capitalisation.
Addex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency. Explore ADXN cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inomin Mines Inc
V:MINE
|
-0.133x |
|
Alliance Pharma plc
LSE:APH
|
0.099x |
|
DOREL INDS INC. A
F:DO4C
|
-0.047x |
|
Horus AG
STU:HRU
|
N/A |
|
Nickel North Exploration Corp
V:NNX
|
-0.101x |
|
Xstate Resources Ltd
AU:XST
|
-0.355x |
|
PREMIER AFRICAN MINERALS
F:0PA
|
N/A |
|
Pittler Maschinenfabrik AG
F:PIT
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. View Addex Therapeutics Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.77 Million | $-2.08 Million | -0.435x | +21.58% |
| 2024-12-31 | $9.68 Million | $-5.37 Million | -0.555x | +92.04% |
| 2023-12-31 | $1.15 Million | $-7.99 Million | -6.977x | -108.55% |
| 2022-12-31 | $4.91 Million | $-16.44 Million | -3.346x | -285.22% |
| 2021-12-31 | $16.93 Million | $-14.71 Million | -0.869x | -4.18% |
| 2020-12-31 | $14.61 Million | $-12.18 Million | -0.834x | -124.41% |
| 2019-12-31 | $25.52 Million | $-9.48 Million | -0.372x | -932.20% |
| 2018-12-31 | $39.24 Million | $1.75 Million | 0.045x | +102.81% |
| 2017-12-31 | $1.34 Million | $-2.13 Million | -1.590x | +87.10% |
| 2016-12-31 | $218.59K | $-2.69 Million | -12.326x | -680.44% |
| 2015-12-31 | $1.66 Million | $-2.63 Million | -1.579x | -105.86% |
| 2014-12-31 | $2.35 Million | $-1.80 Million | -0.767x | +85.28% |
| 2013-12-31 | $3.03 Million | $-15.78 Million | -5.214x | -188.38% |
| 2012-12-31 | $16.29 Million | $-29.45 Million | -1.808x | -130.40% |
| 2011-12-31 | $33.84 Million | $-26.55 Million | -0.785x | -61.27% |
| 2010-12-31 | $64.41 Million | $-31.34 Million | -0.487x | +4.14% |
| 2009-12-31 | $77.58 Million | $-39.38 Million | -0.508x | -239.45% |
| 2008-12-31 | $118.99 Million | $-17.79 Million | -0.150x | +36.53% |
| 2007-12-31 | $140.11 Million | $-33.00 Million | -0.236x | +49.08% |
| 2006-12-31 | $42.28 Million | $-19.56 Million | -0.463x | -- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more